Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis
- PMID: 38888087
- DOI: 10.1111/jpi.12985
Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis
Abstract
Previous studies have reported inconsistent results about exogenous melatonin's sleep-promoting effects. A possible explanation relies on the heterogeneity in administration schedule and dose, which might be accountable for differences in treatment efficacy. In this paper, we undertook a systematic review and meta-analysis of double-blind, randomized controlled trials performed on patients with insomnia and healthy volunteers, evaluating the effect of melatonin administration on sleep-related parameters. The standardized mean difference between treatment and placebo groups in terms of sleep onset latency and total sleep time were used as outcomes. Dose-response and meta-regression models were estimated to explore how time of administration, dose, and other treatment-related parameters might affect exogenous melatonin's efficacy. We included 26 randomized controlled trials published between 1987 and 2020, for a total of 1689 observations. Dose-response meta-analysis showed that melatonin gradually reduces sleep onset latency and increases total sleep time, peaking at 4 mg/day. Meta-regression models showed that insomnia status (β = 0.50, p < 0.001) and time between treatment administration and the sleep episode (β = -0.16, p = 0.023) were significant predictors of sleep onset latency, while the time of day (β = -0.086, p < 0.01) was the only significant predictor of total sleep time. Our results suggest that advancing the timing of administration (3 h before the desired bedtime) and increasing the administered dose (4 mg/day), as compared to the exogenous melatonin schedule most used in clinical practice (2 mg 30 min before the desired bedtime), might optimize the efficacy of exogenous melatonin in promoting sleep.
Keywords: dose−response relationship; drug administration schedule; hypnotics and sedatives; melatonin; sleep initiation and maintenance disorders; sleep wake disorders; time factors.
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
References
-
- G. C. Hisler, D. Muranovic, and Z. Krizan, “Changes in Sleep Difficulties Among the US Population From 2013 to 2017: Results From the National Health Interview Survey,” Sleep Health 5, no. 6 (2019): 615–620, https://doi.org/10.1016/J.SLEH.2019.08.008.
-
- S. Chokroverty, “Approach to the Patient With Sleep Complaints,” in Sleep Disorders Medicine: Basic Science, Technical Considerations and Clinical Aspects, ed. S. Chokroverty (New York: Springer, 2017), 451–473, https://doi.org/10.1007/978-1-4939-6578-6_26.
-
- M. J. Sateia, “International Classification of Sleep Disorders‐Third Edition,” Chest 146, no. 5 (2014): 1387–1394, https://doi.org/10.1378/CHEST.14-0970.
-
- M. Partinen and E. Kronholm, “Epidemiology: Principles and Application in Sleep Medicine,” in Sleep Disorders Medicine: Basic Science, Technical Considerations and Clinical Aspects, ed. S. Chokroverty (New York: Springer, 2017), 485–521, https://doi.org/10.1007/978-1-4939-6578-6_28.
-
- R. J. Ozminkowski, S. Wang, and J. K. Walsh, “The Direct and Indirect Costs of Untreated Insomnia in Adults in the United States,” Sleep 30, no. 3 (2007): 263–273, https://doi.org/10.1093/SLEEP/30.3.263.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical